BIO 1211是一种α4β1（VLA-4）整合素抑制剂，可分别抑制α4β1（IC50=4nM）和α4β7（IC50=2μM）。
Cas No.:187735-94-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
BIO 1211 is an α4β1 (VLA-4) integrin inhibitor, which inhibits α4β1 (IC₅₀=4nM) and α4β7 (IC₅₀=2µM)[1-2]. BIO 1211 reduces leukocyte migration and inflammatory cytokine expression by inhibiting the VLA-4/VCAM-1 interaction. BIO 1211 can be used in research related to inflammatory diseases such as multiple sclerosis (experimental autoimmune encephalomyelitis model) and asthma[3-4].
In vitro, BIO 1211 (50µM) was co-cultured with patient-derived B-ALL bone marrow mononuclear cells and two stromal cell populations (adipogenic progenitor cells and early mesenchymal progenitor cells) for 7 days, effectively reducing the viability of leukemic cells in the co-culture system[5]. IMR-32, CHP-134, and Kelly neuroblastoma cell lines were treated with BIO 1211 (1-5µM) for 72 hours. BIO 1211 significantly decreased cell survival and reduced cell attachment; when combined with the anti-GD2 antibody 14G2a (20 µg/ml), BIO 1211 further enhanced cytotoxicity in IMR-32 cells[6].
In vivo, BIO 1211 (1, 3, 10mg/ml; 2min) was administered via aerosol inhalation to treat SD rats sensitized with albumin. BIO 1211 dose-dependently significantly inhibited the increase in lung resistance and the decrease in dynamic lung compliance caused by antigen challenge[7]. BIO 1211 (1, 3, 10mg/kg) was administered via a single intraperitoneal injection to treat SD rats after glucan gel-induced inflammation. BIO 1211 dose-dependently significantly inhibited the aggregation of peritoneal eosinophils[8].
References:
[1] Bolger GT. BIO-1211 (Biogen). IDrugs. 2000 May;3(5):536-40.
[2] Hagmann WK. The discovery and potential of N-sulfonylated dipeptide VLA-4 antagonists. Curr Top Med Chem. 2004;4(14):1461-71.
[3] Dattoli SD, De Marco R, Baiula M,et al. Synthesis and assay of retro-α4β1 integrin-targeting motifs. Eur J Med Chem. 2014 Feb 12;73:225-32.
[4] Drin G, Cottin S, Blanc E, et al. Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem. 2003 Aug 15;278(33):31192-201.
[5] Ferrao Blanco MN, Kazybay B, Belderbos M, et al. Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment. Leukemia. 2025 Nov;39(11):2622-2639.
[6] Horwacik I, Rokita H. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a. Int J Oncol. 2017 May;50(5):1899-1914.
[7] Dong XW, Du XG, Zhang SJ, et al. Inhibitory effects of BIO-1211 on bronchoconstriction and neutrophil adhesion in rats. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2008 Jul;37(4):340-4.
[8] Zhao XY, Chen JQ, Xie QM, et al. Effects of BIO-1211 on eosinophil chemotaxis, recruitment and mediator release. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2003 Aug;32(4):279-82, 291.
BIO 1211是一种α4β1（VLA-4）整合素抑制剂，可分别抑制α4β1（IC50=4nM）和α4β7（IC50=2μM）[1-2]。BIO 1211通过抑制VLA-4/VCAM-1相互作用来减少白细胞迁移和炎症细胞因子表达。BIO 1211可用于多发性硬化症（实验性自身免疫性脑脊髓炎模型）和哮喘等炎症性疾病的相关研究[3-4]。
在体外，BIO 1211（50μM）与B-ALL患者来源的骨髓单核细胞及两种基质细胞群（脂肪源性祖细胞和早期间充质祖细胞）共培养7天，可有效降低共培养体系中白血病细胞的存活率[5]。BIO 1211（1-5μM）处理IMR-32、CHP-134和Kelly神经母细胞瘤细胞系72小时。BIO 1211显著降低了细胞存活率，并减少了细胞附着；当BIO 1211与抗GD2抗体14G2a（20μg/ml）联合使用时，在IMR-32细胞中进一步增强了细胞毒性[6]。
在体内，BIO 1211（1、3、10mg/ml；2min）通过气雾吸入给药，用于处理卵白蛋白致敏的SD大鼠。BIO-1211呈剂量依赖性地显著抑制了抗原攻击引起的肺阻力升高和动态肺顺应性降低[7]。BIO-1211（1、3、10 mg/kg）通过单次腹腔注射给药，用于处理葡聚糖凝胶致炎后的SD大鼠。BIO 1211呈剂量依赖性地显著抑制了腹腔嗜酸粒细胞的聚集[8]。
| Cell experiment [1]: | |
Cell lines | IMR-32, CHP-134, and Kelly human neuroblastoma cell lines |
Preparation Method | Cells were cultured on fibronectin-coated plates. They were treated with BIO 1211 (1-5μM) alone or in combination with the anti-GD2 monoclonal antibody 14G2a (20μg/ml). |
Reaction Conditions | 1-5μM; 72 hours. |
Applications | BIO 1211 (5μM) induced evident changes in the morphology of IMR-32 cells (e.g., cell rounding) and reduced cell attachment on fibronectin-coated surfaces. Treatment with BIO 1211 (1-5μM) for 72 hours significantly decreased cellular ATP levels (a measure of cell survival) in IMR-32 cells in a concentration-dependent manner, with the most pronounced effect at 5μM. When combined with the 14G2a antibody, BIO 1211 further reduced the survival of IMR-32 cells compared to treatment with the antibody alone. The effects of BIO 1211 on CHP-134 and Kelly cell survival and attachment were minimal. |
| Animal experiment [2]: | |
Animal models | SD rats |
Preparation Method | Rats were intraperitoneally administered a single dose of BIO 1211 (1, 3, 10mg/kg). Two hours later, eosinophil inflammation was induced by a single intraperitoneal injection of Sephadex. Peritoneal lavage fluid was collected 24 hours after Sephadex administration for cell count analysis. |
Dosage form | 1, 3, 10mg/kg; i.p..; single administration. |
Applications | BIO 1211 administration inhibited Sephadex-induced peritoneal eosinophil recruitment in a dose-dependent manner. BIO 1211 did not inhibit eosinophil peroxidase (EPO) release. |
References: | |
| Cas No. | 187735-94-0 | SDF | |
| 化学名 | (2S)-1-[(2S)-2-[[(2S)-3-carboxy-2-[[(2S)-4-methyl-2-[[2-[4-[(2-methylphenyl)carbamoylamino]phenyl]acetyl]amino]pentanoyl]amino]propanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carboxylic acid | ||
| Canonical SMILES | CC1=CC=CC=C1NC(=O)NC2=CC=C(C=C2)CC(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(C(C)C)C(=O)N3CCCC3C(=O)O | ||
| 分子式 | C36H48N6O9 | 分子量 | 708.8 |
| 溶解度 | Soluble to 2 mg/ml in 0.2M PBS | 储存条件 | Store at -20°C, sealed storage, away from moisture and light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4108 mL | 7.0542 mL | 14.1084 mL |
| 5 mM | 282.2 μL | 1.4108 mL | 2.8217 mL |
| 10 mM | 141.1 μL | 705.4 μL | 1.4108 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet